glp-1 tripeptide GLP-1-based therapies for diabetes, obesity and beyond 1 production. Semaglutide & Tirzepatide Weight Loss

B6, B9 B12 , (): , ,

According to the latest epidemiological data, the number of people with diabetes worldwide has reached 529 million in 2021 and is expected to increase to 1.31 billion by 2050 ( In recent years, Glucagon-like peptide-1 receptor (GLP-1R) and its agonists have attracted much attention in the field of diabetes treatment

In the SUSTAIN-6 trial, semaglutide was associated with a significant increased risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation (HR 1.76, 95% CI 1.112.78) [27]

Ozempic is a brand of semaglutide, a class of drug that helps lower blood sugar

Adriane Fugh-Berman at Georgetown University